Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) was the recipient of a significant decrease in short interest during the month of August. As of August 31st, there was short interest totalling 441,830 shares, a decrease of 35.8% from the August 15th total of 688,157 shares. Based on an average daily volume of 239,223 shares, the short-interest ratio is currently 1.8 days. Currently, 3.9% of the shares of the stock are short sold.

In other news, major shareholder Eastern Capital Ltd purchased 850,000 shares of the company’s stock in a transaction dated Wednesday, July 19th. The stock was bought at an average cost of $2.00 per share, for a total transaction of $1,700,000.00. Following the purchase, the insider now owns 2,167,261 shares of the company’s stock, valued at $4,334,522. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 4.00% of the stock is owned by corporate insiders.

Cyclacel Pharmaceuticals (NASDAQ:CYCC) opened at 1.71 on Friday. The company has a 50-day moving average of $1.68 and a 200 day moving average of $3.68. Cyclacel Pharmaceuticals has a 12 month low of $1.56 and a 12 month high of $10.90.

Cyclacel Pharmaceuticals (NASDAQ:CYCC) last posted its earnings results on Wednesday, August 9th. The biotechnology company reported ($0.50) earnings per share (EPS) for the quarter. Cyclacel Pharmaceuticals had a negative net margin of 1,128.13% and a negative return on equity of 68.88%. Analysts predict that Cyclacel Pharmaceuticals will post ($2.25) earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by American Banking News and is owned by of American Banking News. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international trademark and copyright legislation. The original version of this news story can be accessed at

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals, Inc operates in the field of cell cycle biology. The Company has generated various families of anticancer drugs that act on the cell cycle, including nucleoside analogs, cyclin dependent kinase (CDK) inhibitors, polo-like kinase (PLK) inhibitors and Aurora Kinase/vascular endothelial growth factor receptor (AK/VEGFR) inhibitors.

Receive News & Ratings for Cyclacel Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclacel Pharmaceuticals Inc. and related companies with's FREE daily email newsletter.